Solara Active Pharma Sciences Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: June 29, 2025, 8:06 pm

Competitors of Solara Active Pharma Sciences Ltd

All Competitor Stocks of Solara Active Pharma Sciences Ltd

Quarterly Result

Last Updated: May 31, 2025, 7:44 am

Below is a detailed analysis of the quarterly data for Solara Active Pharma Sciences Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 273.01 Cr.. The value appears to be declining and may need further review. It has decreased from 300.31 Cr. (Dec 2024) to 273.01 Cr., marking a decrease of 27.30 Cr..
• For Expenses, as of Mar 2025, the value is 227.64 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 242.63 Cr. (Dec 2024) to 227.64 Cr., marking a decrease of 14.99 Cr..
• For Operating Profit, as of Mar 2025, the value is 45.37 Cr.. The value appears to be declining and may need further review. It has decreased from 57.68 Cr. (Dec 2024) to 45.37 Cr., marking a decrease of 12.31 Cr..
• For OPM %, as of Mar 2025, the value is 16.62%. The value appears to be declining and may need further review. It has decreased from 19.21% (Dec 2024) to 16.62%, marking a decrease of 2.59%.
• For Other Income, as of Mar 2025, the value is 5.95 Cr.. The value appears strong and on an upward trend. It has increased from 1.49 Cr. (Dec 2024) to 5.95 Cr., marking an increase of 4.46 Cr..
• For Interest, as of Mar 2025, the value is 29.12 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 26.54 Cr. (Dec 2024) to 29.12 Cr., marking an increase of 2.58 Cr..
• For Depreciation, as of Mar 2025, the value is 24.30 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 24.54 Cr. (Dec 2024) to 24.30 Cr., marking a decrease of 0.24 Cr..
• For Profit before tax, as of Mar 2025, the value is -2.10 Cr.. The value appears to be declining and may need further review. It has decreased from 8.09 Cr. (Dec 2024) to -2.10 Cr., marking a decrease of 10.19 Cr..
• For Tax %, as of Mar 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00%.
• For Net Profit, as of Mar 2025, the value is -2.10 Cr.. The value appears to be declining and may need further review. It has decreased from 8.09 Cr. (Dec 2024) to -2.10 Cr., marking a decrease of 10.19 Cr..
• For EPS in Rs, as of Mar 2025, the value is -0.58. The value appears to be declining and may need further review. It has decreased from 2.24 (Dec 2024) to -0.58, marking a decrease of 2.82.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 4:01 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: June 16, 2025, 11:19 am

Below is a detailed analysis of the balance sheet data for Solara Active Pharma Sciences Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 40.00 Cr.. The value appears strong and on an upward trend. It has increased from 36.00 Cr. (Mar 2024) to 40.00 Cr., marking an increase of 4.00 Cr..
• For Reserves, as of Mar 2025, the value is 1,054.00 Cr.. The value appears strong and on an upward trend. It has increased from 898.00 Cr. (Mar 2024) to 1,054.00 Cr., marking an increase of 156.00 Cr..
• For Borrowings, as of Mar 2025, the value is 796.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 1,012.00 Cr. (Mar 2024) to 796.00 Cr., marking a decrease of 216.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 342.00 Cr.. The value appears to be improving (decreasing). It has decreased from 406.00 Cr. (Mar 2024) to 342.00 Cr., marking a decrease of 64.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 2,232.00 Cr.. The value appears to be improving (decreasing). It has decreased from 2,351.00 Cr. (Mar 2024) to 2,232.00 Cr., marking a decrease of 119.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 1,193.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,268.00 Cr. (Mar 2024) to 1,193.00 Cr., marking a decrease of 75.00 Cr..
• For CWIP, as of Mar 2025, the value is 280.00 Cr.. The value appears strong and on an upward trend. It has increased from 256.00 Cr. (Mar 2024) to 280.00 Cr., marking an increase of 24.00 Cr..
• For Investments, as of Mar 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 2.00 Cr..
• For Other Assets, as of Mar 2025, the value is 757.00 Cr.. The value appears to be declining and may need further review. It has decreased from 825.00 Cr. (Mar 2024) to 757.00 Cr., marking a decrease of 68.00 Cr..
• For Total Assets, as of Mar 2025, the value is 2,232.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,351.00 Cr. (Mar 2024) to 2,232.00 Cr., marking a decrease of 119.00 Cr..

Notably, the Reserves (1,054.00 Cr.) exceed the Borrowings (796.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Solara Active Pharma Sciences Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 0.14. This value is below the healthy minimum of 5. It has increased from -157.62 (Mar 24) to 0.14, marking an increase of 157.76.
• For Diluted EPS (Rs.), as of Mar 25, the value is 0.14. This value is below the healthy minimum of 5. It has increased from -157.62 (Mar 24) to 0.14, marking an increase of 157.76.
• For Cash EPS (Rs.), as of Mar 25, the value is 24.79. This value is within the healthy range. It has increased from -128.79 (Mar 24) to 24.79, marking an increase of 153.58.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 271.86. It has increased from 260.16 (Mar 24) to 271.86, marking an increase of 11.70.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 271.86. It has increased from 260.16 (Mar 24) to 271.86, marking an increase of 11.70.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 318.95. It has decreased from 358.03 (Mar 24) to 318.95, marking a decrease of 39.08.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 53.32. This value is within the healthy range. It has increased from -24.95 (Mar 24) to 53.32, marking an increase of 78.27.
• For PBIT / Share (Rs.), as of Mar 25, the value is 28.66. This value is within the healthy range. It has increased from -53.65 (Mar 24) to 28.66, marking an increase of 82.31.
• For PBT / Share (Rs.), as of Mar 25, the value is 0.13. This value is within the healthy range. It has increased from -135.67 (Mar 24) to 0.13, marking an increase of 135.80.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 0.13. This value is below the healthy minimum of 2. It has increased from -157.49 (Mar 24) to 0.13, marking an increase of 157.62.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.13. This value is below the healthy minimum of 2. It has increased from -157.61 (Mar 24) to 0.13, marking an increase of 157.74.
• For PBDIT Margin (%), as of Mar 25, the value is 16.71. This value is within the healthy range. It has increased from -6.96 (Mar 24) to 16.71, marking an increase of 23.67.
• For PBIT Margin (%), as of Mar 25, the value is 8.98. This value is below the healthy minimum of 10. It has increased from -14.98 (Mar 24) to 8.98, marking an increase of 23.96.
• For PBT Margin (%), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 10. It has increased from -37.89 (Mar 24) to 0.04, marking an increase of 37.93.
• For Net Profit Margin (%), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from -43.98 (Mar 24) to 0.04, marking an increase of 44.02.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 8. It has increased from -44.02 (Mar 24) to 0.04, marking an increase of 44.06.
• For Return on Networth / Equity (%), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 15. It has increased from -60.75 (Mar 24) to 0.04, marking an increase of 60.79.
• For Return on Capital Employeed (%), as of Mar 25, the value is 8.95. This value is below the healthy minimum of 10. It has increased from -17.42 (Mar 24) to 8.95, marking an increase of 26.37.
• For Return On Assets (%), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from -24.13 (Mar 24) to 0.02, marking an increase of 24.15.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.10. This value is below the healthy minimum of 0.2. It has decreased from 0.11 (Mar 24) to 0.10, marking a decrease of 0.01.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.70. This value is within the healthy range. It has decreased from 1.07 (Mar 24) to 0.70, marking a decrease of 0.37.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.56. It has increased from 0.49 (Mar 24) to 0.56, marking an increase of 0.07.
• For Current Ratio (X), as of Mar 25, the value is 0.77. This value is below the healthy minimum of 1.5. It has increased from 0.64 (Mar 24) to 0.77, marking an increase of 0.13.
• For Quick Ratio (X), as of Mar 25, the value is 0.43. This value is below the healthy minimum of 1. It has increased from 0.35 (Mar 24) to 0.43, marking an increase of 0.08.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.72. This value is below the healthy minimum of 4. It has increased from 1.66 (Mar 24) to 1.72, marking an increase of 0.06.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 1.87. This value is below the healthy minimum of 3. It has increased from -0.85 (Mar 24) to 1.87, marking an increase of 2.72.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.00. This value is below the healthy minimum of 3. It has increased from -2.58 (Mar 24) to 1.00, marking an increase of 3.58.
• For Enterprise Value (Cr.), as of Mar 25, the value is 3,238.30. It has increased from 2,334.27 (Mar 24) to 3,238.30, marking an increase of 904.03.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.21. This value is within the healthy range. It has increased from 1.81 (Mar 24) to 2.21, marking an increase of 0.40.
• For EV / EBITDA (X), as of Mar 25, the value is 13.23. This value is within the healthy range. It has increased from -25.99 (Mar 24) to 13.23, marking an increase of 39.22.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.61. This value is within the healthy range. It has increased from 1.04 (Mar 24) to 1.61, marking an increase of 0.57.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Price / BV (X), as of Mar 25, the value is 1.89. This value is within the healthy range. It has increased from 1.44 (Mar 24) to 1.89, marking an increase of 0.45.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.61. This value is within the healthy range. It has increased from 1.04 (Mar 24) to 1.61, marking an increase of 0.57.
• For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has increased from -0.42 (Mar 24) to 0.00, marking an increase of 0.42.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness